<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586739</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0040</org_study_id>
    <secondary_id>2018-A01833-52</secondary_id>
    <nct_id>NCT03586739</nct_id>
  </id_info>
  <brief_title>Evaluation of Covered Stents Versus Bare Metal Stents for Endovascular Treatment of Chronic Ischemia Mesenteric Disease.</brief_title>
  <acronym>ESTIMEC</acronym>
  <official_title>Evaluation of Covered Stents Versus Bare Metal Stents for Endovascular Treatment of Chronic Atherosclerotic Mesenteric Arterial Disease:a Randomised Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Mesenteric Ischemia (CMI) is defined by one or more arterial digestive lesions,
      responsible for severe mesenteric symptoms. The clinical presentation of CMI is characterized
      by postprandial abdominal pain and weight loss, leading to severe malnutrition. It is a
      frequent pathology which affects preferentially the elderly patients of female sex (70%) with
      cardio-vascular comorbidities. Risk factors include smoking, hypertension, and dyslipidemia.

      Despite medical and diagnostic advances, the morbidity and mortality of CMI remain very high
      (&gt;70%). Optimal management of CMI is based on early diagnosis. Symptomatic patients with CMI
      should be treated without much delay to relief symptoms (present in 43% patients) and prevent
      acute mesenteric ischemia.

      The three visceral arteries affected by atherosclerotic disease are coeliac trunc, inferior
      mesenteric artery and Superior Mesenteric Artery (SMA). The SMA is treated the most
      frequently, because it is the main relevant artery associated with CMI.

      Endovascular treatment (angioplasty and stenting) is considered as the first-line treatment
      for CMI when feasible. It is indicated especially in the case of high grade stenosis or
      occlusion of the Superior Mesenteric Artery. Two types of stents can be used for this
      procedure: bare metal stents (BMS) or covered stents (CS).

      Even if BMS are standard care there is no consensus on the type of stent to use.

      There are very few reported series with large numbers of patients comparing BMS and CS in
      this indication. However, to our knowledge, no results from a randomized study addressing
      this issue have ever been published. These are only retrospective with a low level of
      evidence (IIb). The largest series compared 147 patients with primary intervention for CMI
      treatment using BMS versus 42 using CS. Treatment with CS showed better results in terms of
      symptom recurrence (10% vs 32%, p &lt;0.002), restenosis (12% vs 42%, p &lt;0.0002) and
      re-interventions (10% vs 42%), after at least 1 year of follow-up. Indeed, endovascular
      treatment using BMS was associated with high incidence of symptoms recurrence despite the
      satisfying patency rates in both occluded and stenotic vessels.

      There are no international guidelines to recommend the use of one or another sort of stent.

      The necessity of a randomised study addressing the issue of bare metal versus covered stents
      deployment seems to be important.

      The investigators propose to demonstrate that covered stents presents a better efficacy than
      bare metal stents, with a multicenter randomized study involving 24 vascular surgical
      departments of French University Hospitals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">August 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from restenosis,</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
    <description>Freedom from restenosis will be defined as ≥50% luminal reduction and/or thrombosis, confirmed by CT-scan.
The crude percentage of restenosis and/or thrombosis at 24 months will be computed for each group. The survival curves for freedom from restenosis and/or thrombosis will be plotted according to the Kaplan-Meier method and overall survival rates will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of endovascular procedure complications</measure>
    <time_frame>up to discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with maintained primary, primary assisted and secondary patencies</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with maintained primary, primary assisted and secondary patencies</measure>
    <time_frame>6 months after the primary endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with maintained primary, primary assisted and secondary patencies</measure>
    <time_frame>12 months after the primary endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with maintained primary, primary assisted and secondary patencies</measure>
    <time_frame>18 months after the primary endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularisation (TLR)</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
    <description>Repeat revascularisation for a lesion anywhere within the primary stent or the 5-mm borders proximal or distal to the stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of symptoms recurrence</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
    <description>Clinical recurrence, defined as the symptomatic recurrence of chronic, subacute or acute mesenteric ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of reintervention (endovascular or surgical)</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major morbidity</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
    <description>Occurrence of major morbidity and description of the events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>24 months after the primary endovascular treatment</time_frame>
    <description>quality of life will be compared between the two groups and assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>at inclusion</time_frame>
    <description>quality of life will be compared between the two groups and assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>6 months after the primary endovascular treatment</time_frame>
    <description>quality of life will be compared between the two groups and assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>12 months after the primary endovascular treatment</time_frame>
    <description>quality of life will be compared between the two groups and assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from restenosis</measure>
    <time_frame>12 months after the primary endovascular treatment</time_frame>
    <description>The freedom from restenosis will be defined as ≥50% luminal reduction and/or thrombosis, confirmed by CT-scan.
The crude percentage of restenosis and/or thrombosis at 12 months will be computed for each group. The survival curves for freedom from restenosis and/or thrombosis will be plotted according to the Kaplan-Meier method and overall survival rates will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Chronic Mesenteric Ischemia</condition>
  <condition>Stent Stenosis</condition>
  <arm_group>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular angioplasty using covered stents</intervention_name>
    <description>Primary endovascular angioplasty using one or several covered stents</description>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular angioplasty using bare metal stents</intervention_name>
    <description>Primary endovascular angioplasty using one or several bare metal stents</description>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Duplex-scan</intervention_name>
    <description>a Duplex-scan will be performed during patient follow up.</description>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>computerized tomography scan (CT-scan)</intervention_name>
    <description>a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.
The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up.</description>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>digital angiography</intervention_name>
    <description>In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.</description>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short Form-36 (SF-36) questionnaire</intervention_name>
    <description>The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.</description>
    <arm_group_label>&quot;Bare metal stents&quot; strategy</arm_group_label>
    <arm_group_label>&quot;Covered stents&quot; strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or older;

          -  Diagnosis of chronic atherosclerotic mesenteric ischemia or atherosclerosis
             threatening disorders of digestive perfusion, with stenosis or occlusion of the
             superior mesenteric artery;

          -  For whom a primary endovascular intervention by percutaneous transluminal angioplasty
             using stents has been scheduled (anatomical evaluation, arterial evaluation consistent
             with endovascular treatment);

          -  For an ostial or post-ostial stenotic arterial lesion to be treated by only one type
             of stent authorized in the study according to randomization;

          -  Having signed an informed consent for participation in the study.

        Exclusion Criteria:

          -  Acute mesenteric ischemia;

          -  Previous revascularisation intervention for chronic mesenteric ischemia;

          -  For some stenotic arterial lesion to be treated more than one type of stent;

          -  Chronic renal failure (glomerular filtration rate less than 20 mL per minute);

          -  Low probability of cooperation of the participant (judged by the investigator);

          -  Medical or surgical history judged by the investigator to be not compatible with this
             study;

          -  Adult ward or court (under guardianship or trusteeship);

          -  Pregnant or lactating woman;

          -  Person under judicial protection;

          -  Subject participating in another study having an exclusion period still active.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick FEUGIER, Pr</last_name>
    <phone>04.78.86.12.72</phone>
    <phone_ext>+33</phone_ext>
    <email>patrickfeugier@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soumia BAYARASSOU, Clinical Research Assistant</last_name>
    <phone>04 72 11 51 69</phone>
    <phone_ext>+33</phone_ext>
    <email>soumia.bayarassou01@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean PICQUET, Pr</last_name>
      <phone>02 41 35 38 37</phone>
      <phone_ext>+33</phone_ext>
      <email>jepicquet@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire? CHU J. Minjoz Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon RINCKENBACH, Pr</last_name>
      <phone>03 81 66 80 52</phone>
      <phone_ext>+33</phone_ext>
      <email>srinckenbach@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Vasculaire et Générale, CHU de Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DUCASSE, Pr</last_name>
      <phone>05 56 79 55 25</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.ducasse@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, APHP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael COSCAS, MD, PhD</last_name>
      <phone>01 49 09 53 19</phone>
      <phone_ext>+33</phone_ext>
      <email>rcoscas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Vasculaire, CHU de Brest, Hôpital de La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahaa NASR, MD, PhD</last_name>
      <phone>02 98 34 74 29</phone>
      <phone_ext>+33</phone_ext>
      <email>bahaa.nasr@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Côte de Nacre Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic BERGER, Pr</last_name>
      <phone>02 31 06 44 45</phone>
      <phone_ext>+33</phone_ext>
      <email>berger-l@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Clermont-Ferrand - Hôpital G. Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio ROSSET, Pr</last_name>
      <phone>04 73 7515 10</phone>
      <phone_ext>+33</phone_ext>
      <email>erosset@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, APHP Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic COCHENNEC, MD, PhD</last_name>
      <phone>01 49 81 21 11</phone>
      <phone_ext>+33</phone_ext>
      <email>cochennecf@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Cardio-Vasculaire, CHU Le Bocage Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric STEINMETZ, Pr</last_name>
      <phone>03 80 29 33 52</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.steinmetz@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHRU Hôpital Cardiologique de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan SOBOCINSKI, Pr</last_name>
      <phone>03 20 44 50 05</phone>
      <phone_ext>+33</phone_ext>
      <email>jonathan.sobocinski@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, Centre Hospitalier Saint Philibert, Lomme</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques CHEVALIER, Pr</last_name>
      <phone>03 20 22 50 86</phone>
      <phone_ext>+33</phone_ext>
      <email>sec_chir_vasc_sp@ghicl.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick FEUGIER, Pr</last_name>
      <phone>04.78.86.12.72</phone>
      <phone_ext>+33</phone_ext>
      <email>patrickfeugier@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Marseille - Hôpital la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel-Alain BARTOLI, Pr</last_name>
      <phone>04 91 38 57 62</phone>
      <phone_ext>+33</phone_ext>
      <email>michelalain.bartoli@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Nantes - Hôpital Nord Laënnec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann GOUEFFIC, Pr</last_name>
      <phone>02 40 16 50 93</phone>
      <phone_ext>+33</phone_ext>
      <email>yann.goueffic@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elixene JEAN-BAPTISTE, Pr</last_name>
      <phone>04 92 03 38 35</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-baptiste.e@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, APHP Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GAUDRIC, MD, PhD</last_name>
      <phone>01 42 17 57 40</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.gaudric@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Hervé CASTIER, Pr</last_name>
      <phone>01 40 25 69 62</phone>
      <phone_ext>+33</phone_ext>
      <email>yves.castier@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Hervé CASTIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick FEUGIER, PH</last_name>
      <phone>04.78.86.12.72</phone>
      <phone_ext>+33</phone_ext>
      <email>patrickfeugier@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Patrick FEUGIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Poitiers - Hôpital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>fabrice SCHNEIDER, Pr</last_name>
      <phone>05 49 44 38 46</phone>
      <phone_ext>+33</phone_ext>
      <email>Fabrice.SCHNEIDER@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>fabrice SCHNEIDER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Pontchailloux Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien KALADJI, MD, PhD</last_name>
      <phone>02 99 28 95 69</phone>
      <phone_ext>+33</phone_ext>
      <email>kaladrien@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier PLISSONNIER, Pr</last_name>
      <phone>02 32 88 13 92</phone>
      <phone_ext>+33</phone_ext>
      <email>didier.plissonnier@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Cardio-Vasculaire, CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre FAVRE, Pr</last_name>
      <phone>04 77 82 83 35</phone>
      <phone_ext>+33</phone_ext>
      <email>j.pierre.favre@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Amiens Picardie - Site Sud</name>
      <address>
        <city>Salouël</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry REIX, Pr</last_name>
      <phone>03 22 45 59 35</phone>
      <phone_ext>+33</phone_ext>
      <email>reix.thierry@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Vasculaire, CHU de Strasbourg, Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien THAVEAU, Pr</last_name>
      <phone>03 69 55 06 50</phone>
      <phone_ext>+33</phone_ext>
      <email>fabien.thaveau@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire, CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier CHAUFFOUR, Pr</last_name>
      <phone>05 61 32 39 10</phone>
      <phone_ext>+33</phone_ext>
      <email>chaufour.x@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Vasculaire? CHU Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicla SETTEMBRE, MD, PhD</last_name>
      <phone>03 83 15 43 84</phone>
      <phone_ext>+33</phone_ext>
      <email>nicla.settembre@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenteric Ischemia Chronic</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Primary endovascular treatment</keyword>
  <keyword>Covered stents</keyword>
  <keyword>Bare metal stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesenteric Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

